Hong Kong Media Stock News

Shanghai Electric Group (SEHK:2727) is back in focus after the Singapore International Arbitration Centre dismissed all substantive claims brought by Oxagon Enterprises with prejudice, reducing legal overhang while leaving profit implications dependent on future enforcement. See our latest analysis for Shanghai Electric Group. Despite the legal win, Shanghai Electric Group’s recent 7 day share price return of 3.89% only partly offsets a 30 day share price decline of 15.98%. However, the 1...

AGM approvals put Deep Source Holdings in focus Deep Source Holdings (SEHK:990) is back on investors’ radar after shareholders approved new company bye laws, director re elections and refreshed share issue and repurchase mandates at the 30 June Annual General Meeting. See our latest analysis for Deep Source Holdings. Despite the supportive AGM outcome, Deep Source Holdings’ recent trading has been mixed. The 1 day share price return of 7.27% and 7 day share price return of 3.51% stand against...

Why ANVISA’s GMP certification matters for WuXi Biologics (Cayman) stock WuXi Biologics (Cayman) (SEHK:2269) has just received GMP certification from Brazil's ANVISA for two Wuxi manufacturing facilities and its packaging center, enabling end to end production of an anti PD L1 cancer immunotherapy. See our latest analysis for WuXi Biologics (Cayman). The ANVISA certification arrives at a time when momentum in WuXi Biologics (Cayman) stock has picked up, with a 1 month share price return of...

Sihuan Pharmaceutical Holdings Group (SEHK:460) recently reported that the first patient has been enrolled in a Phase III trial for Anaprazole Sodium Enteric-coated Tablets in Helicobacter pylori treatment, a development that could influence how investors view the stock. See our latest analysis for Sihuan Pharmaceutical Holdings Group. At a share price of HK$0.89, Sihuan Pharmaceutical Holdings Group has seen a 7-day share price return of 7.23%, but the 90-day share price return is down...

Innovent Biologics (SEHK:1801) drew fresh attention after announcing sole commercialization rights for Eli Lilly’s breast cancer drug Verzenios in mainland China, coinciding with a more than 7% jump in the stock. See our latest analysis for Innovent Biologics. Beyond the latest Eli Lilly agreement, Innovent Biologics has reported several oncology milestones this year. The 7 day share price return of 16.83% and 30 day share price return of 14.25% suggest momentum has recently picked up, even...

In June 2026, Geely Automobile Holdings reported a 2% rise in total vehicle sales, powered by very large export growth and a 111% year-on-year jump in deliveries from its premium electric brand ZEEKR. This combination of stronger international demand and rapid electric vehicle momentum underscores how Geely is building a broader global footprint beyond its core China market. We’ll now explore how this surge in exports and ZEEKR’s rapid growth could influence Geely’s existing investment...

Dividend decision and governance update at China Nonferrous Mining China Nonferrous Mining (SEHK:1258) drew fresh attention after shareholders approved a final dividend of US$0.041446 per share and adopted amended articles of association at the 25 June 2026 Annual General Meeting. The dividend is scheduled for payment around 14 July 2026, with shares trading ex dividend on 30 June and a record date of 3 July. This timing often focuses investors on near term income and capital allocation...

As global markets navigate mixed economic signals and regional shifts, the Asian stock landscape presents intriguing opportunities for investors. With manufacturing resilience in China and improved sentiment in Japan, identifying undervalued stocks that could potentially benefit from these conditions is crucial for those looking to capitalize on the evolving market dynamics.

As global markets navigate mixed signals, with U.S. small-cap indices like the Russell 2000 experiencing declines and China's manufacturing sector showing resilience, investors are keenly observing Asia's evolving economic landscape. In this environment, identifying promising stocks often involves looking for companies that demonstrate strong fundamentals and adaptability to shifting market conditions.

With inflation trends uneven across regions and central banks sending mixed signals on rate paths, dependable income can feel hard to find. That is where the Dividend Powerhouses screener comes in, focusing on companies with dividend yields above 5% that are covered by current earnings, growing and relatively stable. While policy debates continue around interest rates, growth and inflation, these stocks aim to put cash in your account today. In this article, you will see three stocks from the...

Shanghai MicroPort MedBot (Group) (SEHK:2252) is in focus after its Toumai Remote laparoscopic surgery robot received the EU CE Mark, opening access to more than 30 European markets and providing formal regulatory recognition of remote surgery. See our latest analysis for Shanghai MicroPort MedBot (Group). The Toumai Remote CE Mark news comes as Shanghai MicroPort MedBot (Group)'s 1 day share price return of 1.57% and 7 day share price return of 4.20% contrast with weaker 30 and 90 day share...

Insiders were net sellers of Onewo Inc.'s ( HKG:2602 ) stock during the past year. That is, insiders sold more stock...

Xiamen Yan Palace Bird's Nest Industry Co., Ltd. ( HKG:1497 ), is not the largest company out there, but it saw a...

The fact that multiple SITC International Holdings Company Limited ( HKG:1308 ) insiders offloaded a considerable...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Whilst it may not be a huge deal, we thought it was good to see that the Starjoy Wellness and Travel Company Limited...

Those following along with China Wantian Holdings Limited ( HKG:1854 ) will no doubt be intrigued by the recent...

Man Wah Holdings Limited ( HKG:1999 ) stock is about to trade ex-dividend in 4 days. The ex-dividend date generally...

As global markets navigate a complex landscape marked by mixed performances in major indices and economic data, investors are increasingly turning their attention to Asia, where resilient manufacturing activity and strategic policy measures are shaping the investment climate. In this context, identifying undervalued stocks that trade below their estimated fair value can offer opportunities for those seeking to capitalize on potential market inefficiencies.

It's been a mediocre week for Want Want China Holdings Limited ( HKG:151 ) shareholders, with the stock dropping 17% to...

As Asian markets navigate a mixed landscape with resilient manufacturing activity in China and shifting sentiment in Japan, investors are keenly observing opportunities that may arise. Penny stocks, though often overlooked, present unique prospects for those seeking growth potential within smaller or newer companies. Despite their traditional reputation as speculative investments, some penny stocks demonstrate robust financial health and can offer intriguing opportunities for long-term success.

China Life Insurance (SEHK:2628) has approved a final dividend of RMB 0.618 per share, equivalent to HK$0.71060, at its 25 June 2026 AGM, giving investors clearer visibility on upcoming income. See our latest analysis for China Life Insurance. The dividend decision comes after a mixed stretch for China Life Insurance’s share price, with a 12.32% 90 day share price return but a year to date share price return that is down 2.64%. At the same time, the 1 year total shareholder return of 57.67%...

Sino Biopharmaceutical (SEHK:1177) is back in focus after China’s regulators approved Peceleganan Spray and accepted a new drug application for tecotabart vedotin, LM-302. These are two pipeline milestones in infection control and advanced gastric cancer. See our latest analysis for Sino Biopharmaceutical. Despite the drug pipeline progress, Sino Biopharmaceutical’s share price tells a mixed story. The HK$4.62 close reflects a 1-day share price return of 4.76% and a 7-day gain of 8.45%, set...

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) has drawn investor attention after new translational research on its sac-TMT and osimertinib combination for EGFR-mutant non small cell lung cancer was published in the journal Cancer Cell. See our latest analysis for Sichuan Kelun-Biotech Biopharmaceutical. The latest Cancer Cell publication and wider sac-TMT trial updates arrive as Sichuan Kelun-Biotech Biopharmaceutical trades at HK$467.6, with a year to date share price return of 16.72%...